MMRGlobal, Inc.

Through our wholly-owned operating subsidiary MMR Inc., the Company's primary business is to license and provide secure and easy-to-use online Personal Health Records ("PHR") and MyEsafeDepositBox storage solutions, including a professional offering to physicians' offices and similar organizations known as MMRPro. Starting in 2005, we began filing for patent protection for our PHR products and services, and we now have patents issued, pending, and applied for in numerous countries around the world. As a result, we have evolved from an operating business selling products to also licensing health information technology patents and other intellectual property. In January 2009, as a result of the Merger, we acquired biotech assets and other intellectual property including anti-CD20 antibodies as well as data and samples from the FavId/Specifid vaccine clinical trials for the treatment of B-cell Non-Hodgkin's lymphoma which the Company continues to work towards maximizing the value of those biotech assets including related biotech patents, anti-CD 20 antibodies, and FavId vaccine technologies acquired by MyMedicalRecords, Inc. through the merger with Favrille. We (formerly Favrille) were incorporated in Delaware in 2000, MMR Inc. was incorporated in Delaware in 2005, and both are headquartered in Los Angeles, CA.

Two separate MyMedicalRecords health IT patents were accepted by the Australia Patent Office in 2015 and subject to Opposition. On January 8, 2015, Australia Patent Application No. 2011307287, "Universal Patient Record Conversion Tool," was accepted by the Australia Patent Office. An opposition was filed on April 21, 2015 by The Crown in the Right of the Commonwealth of Australia (Department of Health). A second opposition was filed on April 22, 2015 by the Medical Software Industry Association, Inc. which aligned itself with the Crown.  In the interim, a divisional application, Australia Patent Application No.2015201900, was filed on October 15, 2015.  Rather than continue to bear the legal costs of defending these patents before the Governmental Department of Health, MMR determined it was in the Company's best interest to withdraw the patent and the divisional application and this action was officially acknowledged by the Australian Government on August 4, 2016, thereby ending any further opposition.  Separately, Australia Patent Application No. 2013212253, "Mobile Platform for Personal Health Records," was also accepted by the Australia Patent Office after which oppositions were filed.  Subsequently, the Company filed a request this quarter for withdrawal of the disputed application and also surrender of a related innovation patent No. 2015101556.  The Australian Government acknowledged these actions on September 13, 2016 and we do not expect any further potential litigation in this matter. MMR continues to maintain two previously issued Australia health IT patents under the title "Method and System for Providing Online Medical Records": Patent No. 2006202057 issued on May 29, 2008 and Patent No. 2008202401 issued on December 24, 2009.

Tbe Company acquired a portfolio of biotech assets developed at a cost of more than $100 million from the Favrille, Inc. Merger completed in January 2009. These assets include, but are not limited to, the exploitation and licensing of patents globally, data and samples from our pre-Merger clinical vaccine trials, the FavId/Specifid idiotype vaccine, and anti-CD20 antibodies. To date, patents for our biotechnology IP have been issued in Australia, China, Japan, Mexico, Singapore, South Korea and European territories in addition to the United States. Two China patents for our monoclonal anti-CD20 antibodies intellectual property titled "Antibodies and Methods for Making and Using Them," were issued most recently as Patent Nos. 201310355119.6 and 200780051557.6 on February 24, 2016.

MMR also plans on entering the medical Cannabis industry by entering into strategic relationships with a group of existing operating companies located domestically and internationally through leveraging MMR's access to the public markets and utilizing our health information technology products, services, and experience to support development stage Cannabis-related businesses. The Company is already talking with groups in Oregon, California, Washington, Canada, and Australia. The Company also perceives opportunities in using its significant tax loss carryforwards while providing access to its proprietary health information technology products, services, and experience to support development stage Cannabis-related businesses.

The Company plans on helping early stage companies entering the Cannabis marketplace attract funding and management expertise while giving them the ability to tap into the public markets for financing of facilities, product distribution, market research, and consulting services. Through MMR's strategic relationships, the Company plans on offering branded products and a suite of vertically integrated services supported by experienced consultants, developers, and manufacturers to assist in the growth and expansion of Cannabis-related businesses. Using the Company's patient Personal Health Records products and services, MMR represents the opportunity to also provide branded patient tracking and operating solution supporting the clinical application of Cannabinoid (CBD) products to improve the health of people suffering from chronic illness and diseases.